Advanced search×

Results of a prospective study for the treatment of unilateral retinoblastoma.

Guillermo L GL Chantada, Adriana C AC Fandiño, Myriam R MR Guitter, Elsa C EC Raslawski, Julieta L JL Dominguez, Julio J Manzitti, María T G MT de Dávila, Pedro P Zubizarreta, and Marcelo M Scopinaro

Pediatr Blood Cancer 55(1):60-6 (2010) PMID 20486172

Few prospective studies about the management of unilateral retinoblastoma with pathology risk factors (PRFs) have been published.

DOI: 10.1002/pbc.22503
Version: za2963e q8zad q8zbd q8zc4 q8zda q8ze0 q8zfe q8zg2
Buy PDF

Similar articles you may find interesting…

  1. A tyrosinase biosensor based on ordered mesoporous carbon-Au/l-lysine/Au nanoparticles for simultaneous determination of hydroquinone and ca...
    Lin Tang, Yaoyu Zhou, and Mengshi Wu

    Analyst (2013) PMID 23671910

    A novel biosensor was developed based on tyrosinase immobilization with ordered mesoporous carbon-Au (OMC-Au), l-lysine membrane and Au nanoparticles on a glassy carbon electrode (GCE). It was applied for the simultaneous determination of dihydroxybenzene isomers using differential p...
    Buy PDF
  2. Real-life effectiveness and tolerability of rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: The EMBRAC...
    Serge Gauthier, Alain Robillard, and on behalf of the EMBRACE investigators

    Curr Med Res Opin (2013) PMID 23647369

    Rivastigmine transdermal patch is effective in maintaining cognitive function over 18 months of treatment in patients with mild-to-moderate AD. The safety profile was comparable to the data in the Canadian product monograph. Lack of a comparator group is a potential limitation of the study....
    Buy PDF
  3. Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Pa...
    Mark E Dudley, Colin A Gross, and Steven A Rosenberg

    J Clin Oncol (2013) PMID 23650429

    PURPOSEAdoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can cause durable tumor regressions. The optimal TIL product for ACT is unknown. PATIENTS AND METHODSPatie...
    Buy PDF